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Abstract
OBJECTIVE—To estimate the cost-effectiveness of testing pregnant women with hepatitis B 
(hepatitis B surface antigen [HBsAg]-positive) for hepatitis B e antigen (HBeAg) or hepatitis B 
virus (HBV) DNA, and administering maternal antiviral prophylaxis if indicated, to decrease 
breakthrough perinatal HBV transmission from the U.S. health care perspective.
METHODS—A Markov decision model was constructed for a 2010 birth cohort of 4 million 
neonates to estimate the cost-effectiveness of two strategies: testing HBsAg-positive pregnant 
women for 1) HBeAg or 2) HBV load. Maternal antiviral prophylaxis is given from 28 weeks of 
gestation through 4 weeks postpartum when HBeAg is positive or HBV load is high (108 
copies/mL or greater). These strategies were compared with the current recommendation. All 
neonates born to HBsAg-positive women received recommended active-passive 
immunoprophylaxis. Effects were measured in quality-adjusted life-years (QALYs) and all costs 
were in 2010 U.S. dollars.
RESULTS—The HBeAg testing strategy saved $3.3 million and 3,080 QALYs and prevented 
486 chronic HBV infections compared with the current recommendation. The HBV load testing 
strategy cost $3 million more than current recommendation, saved 2,080 QALYs, and prevented 
324 chronic infections with an incremental cost-effectiveness ratio of $1,583 per QALY saved 
compared with the current recommendations. The results remained robust over a wide range of 
assumptions.
CONCLUSION—Testing HBsAg-positive pregnant women for HBeAg or HBV load followed 
by maternal antiviral prophylaxis if HBeAg-positive or high viral load to reduce perinatal hepatitis 
B transmission in the United States is cost-effective.
An estimated 5,000–8,000 persons who become infected with hepatitis B virus (HBV) 
develop chronic HBV annually.1 Perinatal HBV exposure is an important source of chronic 
HBV. Approximately 24,000 neonates are born to mothers positive for hepatitis B surface 
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antigen (HBsAg) annually in the United States.2,3 Without intervention, more than 30% 
(approximately 7,200) of these neonates will become HBV-infected.4 Approximately 90% 
of HBV-infected neonates will develop chronic HBV4 and have a 25% risk of premature 
death from liver failure or hepatocellular carcinoma.1,3,4 Active-passive immunoprophylaxis 
with hepatitis B vaccination and hepatitis B immune globulin potentially reduces chronic 
HBV infections to 5% or less (approximately 1,200) of perinatally exposed neonates. In this 
scenario, almost all of the neonates with HBV infection are born to pregnant women with 
high HBV load, the most important factor predicting breakthrough infections. High HBV 
load is measured in peripheral blood directly by quantifying the amount of HBV DNA in 
serum or is estimated by detecting hepatitis B e antigen (HBeAg), which strongly correlates 
with high HBV load.5–7
Maternal antiviral prophylaxis during pregnancy (eg, lamivudine, telbivudine, or tenofovir), 
in addition to active-passive immunoprophylaxis for neonates, might prevent 70% of 
perinatal breakthrough infections, possibly by suppressing HBV replication.8–11 However, 
maternal antiviral prophylaxis is not currently the standard of care in the United States.1 The 
objective of this study was to estimate the cost-effectiveness of testing for HBeAg or HBV 
load among HBsAg-positive pregnant women followed by maternal antiviral prophylaxis if 
indicated in addition to the recommended active-passive immunoprophylaxis for their 
neonates.
MATERIAL AND METHODS
Based on the 2010 estimate of live births in the United States,12 we used a birth cohort of 4 
million neonates. We constructed a decision tree model to estimate the costs and effects of 
two sequential testing strategies:
1. Sequential HBeAg testing: among HBsAg-positive pregnant women, test for 
HBeAg followed by maternal antiviral prophylaxis if positive
2. Sequential HBV load testing: among HBsAg-positive pregnant women, determine 
HBV load followed by maternal antiviral prophylaxis if indicated for high HBV 
load.
In these two strategies, all women are routinely screened for HBsAg, and all neonates born 
to HBsAg-positive women receive recommended active-passive immunoprophylaxis with a 
hepatitis B vaccine dose and hepatitis B immune globulin starting within 12 hours of birth 
followed by completion of the hepatitis B vaccine series. We compared the costs and effects 
of the two sequential maternal testing strategies with those of the current recommendation13: 
HBsAg screening for all pregnant women. Neonates born to HBsAg-positive women receive 
active-passive immunoprophylaxis.13 Neonates born to HBsAg-negative women receive a 
“birth dose” of hepatitis B vaccine before hospital discharge (within 72 hours of birth) 
followed by completion of the hepatitis B vaccine series.13 We also estimated the costs and 
effects of two additional strategies:
1. No intervention: no HBsAg screening for pregnant women and no prophylaxis or 
hepatitis B vaccination for their neonates
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2. Neonate vaccination only: no HBsAg screening for pregnant women and a 
complete hepatitis B vaccine series starting within 72 hours of birth without 
hepatitis B immune globulin.
We constructed a Markov model to estimate the lifetime cost (in 2010 U.S. dollars) and 
effects (quality-adjusted life-years [QALY]) associated with acquiring chronic HBV 
infection for neonates. The Markov model of chronic HBV infection includes a set of health 
states: inactive carrier, active chronic HBV infection, cirrhosis, decompensated cirrhosis, 
hepatocellular carcinoma, liver transplantation, and death.14 Life expectancy is 
approximately 78 years in the United States; we used a life cycle of 80 years.15 Like in 
previous studies, the natural history of chronic HBV in a general population is used to model 
the natural history of perinatally acquired chronic HBV, which is not well described.16 Most 
perinatally infected neonates remain in the immune-tolerant stage during childhood; 
although significant complications can occur at a young age, most do not occur until 
adulthood. Therefore, we assumed that complications start at age 20 years, like in previous 
studies.17,18
The baseline parameter values (including plausible ranges) used in the decision tree and 
Markov model are summarized in Table 1. The overall prevalence of HBsAg among 
pregnant women was estimated at 0.6%.2,3,19 Without intervention, we estimated an overall 
perinatal transmission rate of 35.7% for HBsAg-positive women combining the proportional 
transmission rates for HBeAg-positive and HBeAg-negative women.4,6,20 We considered a 
three-dose hepatitis B vaccination series (without hepatitis B immune globulin) to be 72% 
efficacious for preventing perinatal infection.20 The overall perinatal transmission rate was 
approximated at 5% with active-passive immunoprophylaxis.7,21,22 We assumed 90% of 
HBV-infected neonates will develop chronic HBV.1,4,17
The prevalence of HBeAg and high viral load, and perinatal transmission rates among 
neonates, were based on ranges reported in the literature and the assumption that, without 
antiviral prophylaxis during pregnancy, transmission rates for sequential HBeAg testing and 
sequential HBV load testing had to equal the transmission rate with the current 
recommendation. For example, the transmission rate was estimated at 5% under the current 
recommendation. If the prevalence of HBeAg positivity among HBsAg-positive women is 
30%, and the perinatal transmission rate for HBeAg-positive women is 15%,6,23–26 then the 
prevalence of HBeAg negativity among HBsAg-positive women is 70%, and the perinatal 
transmission rate for neonates born to HBeAg-negative women would be 0.71%, because 
the overall perinatal transmission rate remains 5% ([30%×15%]+[70%×0.71%]=5%).
We defined a high HBV load as 108 copies/mL or greater. The perinatal transmission rates 
start to increase as the HBV load reaches 106 copies/mL or greater.7 Because prevalence 
data for women with HBV load higher or lower than 106 copies/mL are limited, we used 106 
copies/mL or greater as the lower limit of value defined as high viral load for sensitivity 
analyses.7,18,25,27,28 Approximately 10–30% of persons with chronic HBV have viral load 
108 copies/mL or greater.7,25–27 Consequently, we chose 20% prevalence as our base 
estimate. The estimated perinatal transmission rates for pregnant women with HBV load 108 
copies/mL or greater ranges from 7 to 32%; we used 15% as the base estimate.7,25–27
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Meta-analyses suggest that in addition to active-passive immunoprophylaxis, maternal 
antiviral prophylaxis can reduce perinatal transmission by 68% (range 37–85%).8,29 We 
chose a 50% reduction rate as our base estimate. We assumed all pregnant women with 
HBeAg or high HBV load will accept antiviral prophylaxis (ie, a 4-month course of 
lamivudine, 100 mg orally once daily from 28 weeks of gestation through 4 weeks 
postdelivery18).
The disease-specific mortality rate and annual transition rates among chronic HBV infection 
health states were estimated from the natural history of hepatitis B in the general 
population.1,27,30–35 We assumed all cases of cirrhosis come from chronic HBV, and all 
decompensated cirrhosis come from cirrhosis (Table 1).
Costs and QALYs were derived from the literature.1,18,27,30–34,36 The cost was adjusted to 
reflect 2010 U. S. dollars using the medical care component of the consumer price index for 
All Urban Consumers.37 We conducted the analyses from the health care system’s 
perspective. Data describing the societal costs such as productivity loss and caregivers’ costs 
were not available. Therefore, we used the health care system’s costs to estimate the cost to 
save 1 QALY. The base cost for antiviral prophylaxis was for a 4-month course of 
lamivudine. Depending on the choice of antiviral drugs, the cost for a 4-month course ranges 
from $1,000 to $4,000.1,18,30,32 We assumed a $100 cost for annual monitoring (ie, office 
visits, HBsAg, and HBeAg tests)30 for chronic HBV in the first 20 years for those infected 
through perinatal transmission (Table 1).
We performed one-way sensitivity analyses on each variable and ranked the range of 
incremental cost-effectiveness ratios to determine the most influential variables. We then 
used these variables to conduct a multiway probabilistic sensitivity analysis (ie, a Monte 
Carlo analysis with 10,000 simulations) to investigate how changes in these variables would 
affect the estimated incremental cost-effectiveness ratio (measured in dollars per QALY 
saved). Parameters of the distribution for the variables (such as a and β for β distribution and 
µ and λ for lognormal distribution) are not available; therefore, we used a triangular 
distribution, which requires the minimum, likeliest, and maximum values for all variables.
Both outcomes (costs and QALYs) were discounted at a 3% annual rate.38 We calculated 
the incremental cost-effectiveness ratio for each strategy compared with the current 
recommendation. TreeAge Pro 2012 was used to build the decision tree and Markov model. 
Institutional review board approval was not required because we used secondary data for 
this study.
RESULTS
We determined the number of neonates with perinatal HBV infection and their lifetime 
complications for each of the interventions compared with the base case (Table 2). The no 
intervention strategy had the highest number of children (7,711) who developed chronic 
HBV. Among the 7,711 children, 1,316 would develop hepatocellular carcinoma, 1,227 
would develop decompensated cirrhosis, and 251 would need a liver transplant. The infant 
vaccination only strategy had the second highest number of infants who developed chronic 
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HBV and the sequential HBV load testing strategy using 106 copies/mL or greater as the 
cutoff for high viral load had the lowest number of children who developed chronic HBV 
(Table 2). Compared with no intervention and infant vaccination only, the current 
recommendation was cost-effective with an incremental cost-effectiveness ratio of $7,146 
and $6,358 per QALY saved, respectively (Table 3). Compared with the current 
recommendation, sequential HBeAg testing saved 3,080 QALYs and $3.3 million (cost-
saving), and the sequential HBV load testing using 108 copies/mL or greater saved 2,080 
QALYs with a cost of $3.3 million (incremental cost-effectiveness ratio: $1,583 per QALY 
saved). Sequential HBeAg testing dominated sequential HBV load testing using 108 
copies/mL or greater with 1,000 QALYs and $6.6 million saved.
Results for the one-way sensitivity analyses are presented in Table 4. Both strategies 
remained cost-effective throughout the range of values used in the sensitivity analyses. The 
most influential variables were the cost and efficacy of antiviral prophylaxis. When the cost 
of antiviral prophylaxis increased from $800 to $4,000, the incremental cost-effectiveness 
ratios for sequential HBeAg testing and sequential HBV load testing using 108 copies/mL or 
greater increased to $4,540 and $7,172 per QALY saved, respectively. When the antiviral-
associated reduction of perinatal transmission decreased from 80% to 20%, the incremental 
cost-effectiveness ratios for sequential HBeAg testing and sequential HBV load testing 
increased to $4,708 and $11,167 per QALY saved, respectively. Other influential variables 
affecting the incremental cost-effectiveness ratios included lifetime chronic HBV costs and 
QALY, perinatal transmission rate, the cost of HBV load testing, and the proportion of 
women receiving antiviral prophylaxis when this strategy is applied.
Results of the probabilistic sensitivity analysis focusing on the influential variables (from 
Table 4) are presented in Table 5. Both strategies remained cost-effective compared with the 
current recommendation. The maximum incremental cost-effectiveness ratios were $20,796 
and $29,708 per QALY saved for sequential HBeAg testing and sequential HBV load 
testing, respectively.
We also examined 106 copies/mL or greater as the value defining high HBV load. Compared 
with the current recommendation, sequential HBV load testing with 106 copies/mL or 
greater HBV load prevented 551 chronic HBV infections, 94 hepatocellular carcinoma 
cases, 83 decompensated cirrhosis cases, 18 liver transplants, and saved 3,440 QALYs at a 
cost of $8.0 million. Applying 106 copies/mL or greater to define a high HBV load saved 
360 more QALYs with approximately $11.3 million in costs compared with sequential 
HBeAg testing (incremental cost-effectiveness ratio: $31,389 per QALY) and saved 1,360 
more QALYs with approximately $4.7 million in costs compared with sequential HBV load 
testing with 108 copies/mL or greater defining high viral load (incremental cost-
effectiveness ratio: $3,456 per QALY). In the one-way and multiway probabilistic 
sensitivity analyses, sequential HBV load testing with 106 copies/mL or greater remained 
cost-effective compared with the current recommendation (Tables 2–5).
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Our study demonstrated that either sequential HBeAg testing or sequential HBV load testing 
was cost-effective under a wide range of assumptions compared with the current 
recommendation. The cost-effectiveness of sequential HBeAg testing and sequential HBV 
load testing relies on several factors, including the cost and efficacy of maternal antiviral 
prophylaxis and lifetime costs associated with chronic HBV infection.
Several studies have concluded that maternal antiviral prophylaxis among HBsAg-positive 
women during pregnancy, in addition to active-passive immunoprophylaxis for the neonate, 
is cost-effective or cost-saving.1,18,27 The purpose of sequential HBeAg testing and HBV 
load testing is to identify HBsAg-positive women whose neonates have the highest risk for 
perinatal transmission. If maternal antiviral prophylaxis is cost-effective in preventing 
perinatal HBV infection among the general population of HBsAg-positive women, 
identification of the highest risk population using HBeAg testing or HBV load testing is 
likely to be cost-effective, because the cost of testing for HBeAg or DNA is small compared 
with the cost of antiviral prophylaxis during pregnancy.
Several antivirals (ie, lamivudine, tenofovir, and telbivudine) reduce HBV viral load and 
might reduce perinatal HBV transmission.9–11 Although lamivudine is the most studied 
maternal antiviral for preventing HBV perinatal transmission, tenofovir or telbivudine has 
been considered because they effectively reduce HBV load with lower rates of drug 
resistance than lamivudine.18,39,40 We do not expect the choice of antiviral agent alone to 
change the cost-effectiveness given the results from sensitivity analyses.
Although HBeAg testing is less expensive than HBV load testing, HBeAg testing can miss a 
small proportion of women with negative HBeAg but high HBV load.41 In our baseline 
assumption, sequential HBeAg testing dominated sequential HBV load testing using 108 
copies/mL or greater as the cutoff value for high viral load (lower cost, higher QALY saved 
for HBeAg testing). However, results of a comparison between the two strategies depends 
on the cutoff for high HBV load, the costs of HBeAg and HBV load testing, the prevalence 
of HBeAg and high HBV load among HBsAg-positive pregnant women, and the perinatal 
transmission rates. Sequential HBV load testing using 106 copies/mL or greater has an 
incremental cost-effectiveness ratio of $31,389 per QALY saved compared with sequential 
HBeAg testing.
This study has several limitations. First, all limitations associated generally with models are 
applicable because our model is a simplification of real-world events. Second, the validity of 
models and the results depend largely on the availability and reliability of the data. We used 
parameter values that varied substantially. As a result of lack of data on the parameters of 
the distribution for each variable, we used a triangular distribution for all variables. Using 
different distributions might change the results of the probabilistic sensitivity analyses. 
However, it is difficult to determine the magnitude or direction of any change. We assumed 
that the rates of adverse events for pregnant women and children from maternal antiviral 
prophylaxis were similar to those without maternal antiviral prophylaxis. Had we included 
complications attributable to antiviral therapy, the cost-effectiveness estimates for the 
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strategies that included antiviral therapy would be higher (less favorable). An increasing 
body of evidence shows that the incidences of adverse events and birth defects among 
pregnant women and children associated with antiviral prophylaxis are comparable to those 
without antiviral prophylaxis.8,10,11,39,40,42 Our results might be conservative because we 
did not include the potential benefit of identifying women who should be treated or 
monitored for liver disease during pregnancy.
Drug resistance from long-term use of lamivudine has been a concern; however, the rate of 
drug resistance after a 3-month course of lamivudine is reported to be no higher than no 
antiviral prophylaxis.1,8,18 Tenofovir and telbivudine have low rates or no documented drug 
resistance when used in other settings.10,11,43 Another safety concern is postpartum 
flare.18,44,45 Studies report mixed results regarding change in the rate of postpartum flares 
after maternal antiviral prophylaxis.45,46 Because evidence for the safety of antiviral 
prophylaxis during pregnancy is still accumulating, antiviral prophylaxis for maternal liver 
disease during pregnancy has generally been postponed.16,47
Despite these limitations, our results suggest that health care providers might wish to 
consider HBeAg or HBV load sequential testing for HBsAg-positive pregnant women to 
identify women whose neonates are at increased risk for perinatal HBV infection and to 
ensure evaluation and monitoring of the pregnant women for the complications of chronic 
HBV infection, including during pregnancy and in the postpartum period.
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Prevalence of HBsAg among pregnant women 0.6% 0.4–0.8% 3,19,48
Risk of perinatal transmission without vaccination 35.7% Calculated 4,6,20,49
Vaccine efficacy (three-dose) 72% 20,49
Risk of perinatal transmission with active-passive immunoprophylaxis 5% 2–8% 1,7,21,22
Likelihood of symptoms after perinatal infection 1% 4
Risk of fulminant hepatitis after symptomatic infection 0.1% 4
Risk of chronic HBV infection after perinatal infection 90% 1,4,17
Risk of chronic HBV infection after fulminant hepatitis 33.3% 4
Risk of death from fulminant hepatitis 70% 4
Prevalence of HBeAg among HBsAg-positive persons 30% 13.5–45% 6,23,25,27,30
Risk of perinatal transmission among HBeAg-positive women with active-
passive immunoprophylaxis
15% 7–23% 6,23–26
Risk of perinatal transmission among HBeAg-negative women with active-
passive immunoprophylaxis
0.71% Calculated
Prevalence of HBsAg-positive women with viral load 108 copies/mL or greater 20% 8–34% 7,25,27
Risk of perinatal transmission among women with viral load 108 copies/mL or
greater with active-passive immunoprophylaxis
15% 8–36% 7,25–27
Risk of perinatal transmission among women with viral load less than 108
copies/mL with active-passive immunoprophylaxis
2.5% Calculated
Prevalence of HBsAg-positive women with viral load 106 copies/mL or greater 50% 31–51% 7,25,34
Risk of perinatal transmission among women with viral load 106 copies/mL or greater with 
active-passive immunoprophylaxis
10% 6–15% 7,26
Risk of perinatal transmission among women with viral load less than
106 copies/mL with active-passive immunoprophylaxis
0% Calculated
Reduction from lamivudine 50% 37–85% 8,29
Transitional probabilities, disease-specific mortality
    Inactive carrier
      Chronic hepatitis B 7.3% 0.3–7.3% 27,33,35
      Mortality 0 Assumption
    Chronic hepatitis B
      Inactive carrier 17% 10.5–42% 33,35
      Cirrhosis 5% 0.4–15.3% 1,33,35
      Hepatocellular carcinoma 0.5% 0.2–0.7% 33,35
      Mortality 2.5% 1.8–3.6% 31
    Cirrhosis
      Decompensated cirrhosis 5.4% 2.8–10% 1,27,31–33
      Hepatocellular carcinoma 2.4% 0.5–3% 1,27,31–33
      Mortality 3.7% 3–4.4% 31,33,35
    Decompensated cirrhosis
    Hepatocellular carcinoma 2.4% 1–10% 1,27,31–33
      Transplant 1.8% 1–10% 1,27,31–33,35

















      Mortality 39% 22.5–50% 31,33,35
    Hepatocellular carcinoma
      Transplant 4.6% 3.6–40% 1,27,31–33,35
      Mortality 56% 26–70% 31,33,35
    Transplant
      First year mortality 15% 1,33,35
      Second year mortality 1.5% 14,35
Cost (U.S. dollars)
Antiviral prophylaxis for 4 mo 1,600 800–4,000 1,18,30,32
HBV load test 240 50–500 18,30,34,36
Hepatitis B immunoglobulin 731 60–731 4,18,32
HBeAg test 30 30,36
Infant acute 468 208–12,304 4,30,33
Infant fulminant 19,000 13,000–52,322 4,30,33
Inactive carrier 100 60–2,130 33
Chronic HBV 1,170 761–6,980 1,18,30–33,50
Cirrhosis 1,519 227–37,380 1,18,30–33,50
Decompensated cirrhosis 17,623 11,459–102,800 1,18,30–33,50
Hepatocellular carcinoma 11,585 7,533–108,950 1,18,30–33,50
Transplant 133,117 86,552–328,407 1,18,30–33,50
Posttransplant 19,317 12,560–31,681 1,18,30–33,50
Effectiveness (QALY)
Carrier 1 0.95–1 1,27,30
Chronic 0.99 0.9–1 1,27,30
Compensated 0.8 0.7–0.9 1,27,30
Decompensated cirrhosis 0.6 0.5–0.7 1,27,30
Hepatocellular carcinoma 0.73 0.5–0.8 1,27,30
Transplant 0.86 0.7–0.9 1,27,30
HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus; HBeAg, hepatitis B e antigen; QALY, quality-adjusted life-years.
*
The specified ranges were used in one-way sensitivity analyses and Monte Carlo simulations.
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Table 4
Most Influential Variables* for Cost-Effectiveness of Sequential Testing Strategies Compared With the 
Current Strategy
Variable Range






Use 108 copies/mL or greater as cutoff value for high viral
load
    Cost of antiviral prophylaxis $800–4,000 for 4
mo
Cost saving–4,540 Cost saving–7,172
    Reduction of perinatal transmission rates from antiviral 20–80% Cost saving–4,708 Cost saving–11,167
    prophylaxis reduction
    Lifetime cost for chronic hepatitis B $26,800–48,400 Cost saving Cost saving–2,285
    Lifetime QALYs for chronic hepatitis B† 37.78–43.21 Cost saving 1,093–2,743
    Perinatal transmission rate 2–8% Cost saving–2,316 Cost saving–7,167
    Cost for HBV load test $50–500 Cost saving‡ Cost saving–4,582
    HBV prevalence among pregnant women 0.4–0.8% Cost saving 1,567–1,590
    Proportion of women receiving antiviral prophylaxis 50–100% Cost saving 1,582–7,209
Use 106 copies/mL or greater as cutoff value for high viral
load
    Cost of antiviral prophylaxis $800–4,000 for 4
mo
Cost saving–4,540 Cost saving–10,711
    Reduction of perinatal transmission rates from antiviral 20–80% Cost saving–4,708 Cost saving–13,378
    prophylaxis reduction
    Lifetime cost for chronic hepatitis B† $26,800–48,400 Cost saving Cost saving–3,047
    Lifetime QALY for chronic hepatitis B† 37.78–43.21 Cost saving 1,622–3,944
    Perinatal transmission rate 2–8% Cost saving–2,316 Cost saving–6,138
    Cost for HBV load test $50–500 Cost saving‡ 1,013–4,153
    HBV prevalence among pregnant women 0.4–0.8% Cost saving 2,312–2,352
    Proportion of women receiving antiviral prophylaxis 50–100% Cost saving 2,339–6,005
QALY, quality-adjusted life years; HBeAG, hepatitis B e antigen; HBV, hepatitis B virus.
*
The influential variables were determined by ranking the cost-effectiveness ratio range in the one-way sensitivity analyses for the model variable 
input, both costs and QALYs were discounted at a 3% annual rate.
†
Discounted at 3% annual rate; low-end lifetime cost and QALYs from chronic hepatitis B infection are 10% percentile cost and QALYs from 
Markov model; high-end lifetime cost and QALYs from chronic hepatitis B infection are 90% percentile cost and QALYs from Markov model.
‡
Remains unchanged because HBV DNA testing does not apply to current recommendation or sequential HBeAg testing.
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Table 5
Multiway Probabilistic Sensitivity Analysis* of Sequential Testing Strategies Compared With the Current 
Recommendation
Incremental Cost-Effectiveness Ratio ($/QALY saved)
108 Copies/mL or Greater for High Viral Load 106 Copies/mL or Greater for High Viral Load
HBeAg Test HBV Load Test HBeAg Test HBV Load Test
Mean Cost-saving 3,151 Cost-saving 4,500.1
2.5%† Cost-saving Cost-saving Cost-saving Cost-saving
10% Cost-saving Cost-saving Cost-saving 81
50% Cost-saving 2,519 Cost-saving 3,587
90% 3,172 7,642 3,178 10,055
97.5% 6,120 12,108 6,092 15,374
Maximum 20,796 29,708 15,188 30,760
QALY, quality-adjusted life years; HBeAG, hepatitis B e antigen; HBV, hepatitis B virus.
*
Based on Monte Carlo analysis with 10,000 simulations. Costs and QALYs were discounted at a 3% annual rate.
†
Represents 2.5 percentile of the cost-effectiveness ratio.
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